WallStSmart

biote Corp (BTMD)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 34853% more annual revenue ($65.77B vs $188.16M). MRK leads profitability with a 13.6% profit margin vs 8.3%. BTMD trades at a lower P/E of 5.1x. MRK earns a higher WallStSmart Score of 50/100 (D+).

BTMD

Hold

35

out of 100

Grade: F

Growth: 3.3Profit: 6.5Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.77

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTMDUndervalued (+47.8%)

Margin of Safety

+47.8%

Fair Value

$4.06

Current Price

$2.10

$1.96 discount

UndervaluedFair: $4.06Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.60

$39.64 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTMD2 strengths · Avg: 10.0/10
P/E RatioValuation
5.1x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-1.9310/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

BTMD4 concerns · Avg: 2.5/10
Market CapQuality
$77.86M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

EPS GrowthGrowth
-83.8%2/10

Earnings declined 83.8%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BTMD

The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BTMD

The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

BTMD carries more volatility with a beta of 1.66 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 35/100). BTMD offers better value entry with a 47.8% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

biote Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

biote corp. The company is headquartered in Irvine, Texas.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?